Selective and reversible inhibitors of ubiquitin-specific protease 7: A patent evaluation (WO2013030218)

Expert Opinion on Therapeutic Patents

Volumn 24, Issue 5, 2014, Pages 597-602

  Kessler, Benedikt M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Anti inflammatory; Anticancer treatment; Protease; Small molecule inhibitor; Ubiquitin; Ubiquitin specific protease 7

Indexed keywords

CASPASE 3; DEUBIQUITINASE; PROTEINASE INHIBITOR; UBIQUITIN SPECIFIC PROTEASE 7; UBIQUITIN SPECIFIC PROTEASE 7 INHIBITOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; QUINAZOLINONE DERIVATIVE; UBIQUITIN THIOLESTERASE; USP7 PROTEIN, HUMAN;

ARTICLE; BACTERIAL INFECTION; CARDIOVASCULAR DISEASE; CELL VIABILITY; CROSS REACTION; CYTOKINE RELEASE; DIABETES MELLITUS; DNA DAMAGE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; IC 50; IN VITRO STUDY; PATENT; PROTEIN INTERACTION; VIRUS INFECTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PATENTS AS TOPIC; PROTEASE INHIBITORS; QUINAZOLINONES; UBIQUITIN THIOLESTERASE;

EID: 84899094611     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2014.882320     Document Type: Article

References (31)

1. Clague MJ, Urbe S. Ubiquitin: same molecule, different degradation pathways. Cell 2010;143(5):682-5
2. Komander D, Rape M. The ubiquitin code. Annu Rev Biochem 2012;81:203-29
3. Kulathu Y, Komander D. Atypical ubiquitylation - the unexplored world of polyubiquitin beyond Lys48 and Lys63 linkages. Nat Rev Mol Cell Biol 2012;13(8):508-23
4. Katz EJ, Isasa M, Crosas B. A new map to understand deubiquitination. Biochem Soc Trans 2010;38(Pt 1):21-8
5. Nijman SM, Luna-Vargas MP, Velds A, et al. A genomic and functional inventory of deubiquitinating enzymes. Cell 2005;123(5):773-86
6. Nicholson B, Suresh Kumar KG. The multifaceted roles of USP7; new therapeutic opportunities. Cell Biochem Biophys 2011;60(1-2):61-8
7. Colland F, Formstecher E, Jacq X, et al. Small-molecule inhibitor of USP7/ HAUSP ubiquitin protease stabilizes and activates p53 in cells. Mol Cancer Ther 2009;8(8):2286-95
8. Nicholson B, Marblestone JG, Butt TR, Mattern MR. Deubiquitinating enzymes as novel anticancer targets. Future Oncol 2007;3(2):191-9
9. Edelmann MJ, Nicholson B, Kessler BM. Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases. Expert Rev Mol Med 2011;13:e35
10. Colland F. The therapeutic potential of deubiquitinating enzyme inhibitors. Biochem Soc Trans 2010;38(Pt 1):137-43
11. van Loosdregt J, Fleskens V, Fu J, et al. Stabilization of the transcription factor Foxp3 by the deubiquitinase USP7 increases Treg-cell-suppressive capacity. Immunity 2013;39(2):259-71
12. Holowaty MN, Sheng Y, Nguyen T, et al. Protein interaction domains of the ubiquitin-specific protease, USP7/HAUSP. J Biol Chem 2003;278(48):47753-61
13. Jacq X, Kemp M, Martin NM, Jackson SP. Deubiquitylating enzymes and DNA damage response pathways. Cell Biochem Biophys 2013;67(1):25-43
14. Gao Y, Koppen A, Rakhshandehroo M, et al. Early adipogenesis is regulated through USP7-mediated deubiquitination of the histone acetyltransferase TIP60. Nat Commun 2013;4:2656
15. Chauhan D, Tian Z, Nicholson B, et al. A small molecule inhibitor0of ubiquitinspecific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell 2012;22(3):345-58
16. Fan YH, Cheng J Vasudevan SA, et al. USP7 inhiritor P22077 inhibits neuroblastma growth via inducing p53-mediqted apoptosis. Cell Death Dis 2013;4:e867
17. Colleran A, Collins PE, OCarroll C, et al. Deubiquitination of NF-kappaB by Ubiquitin-Specific Protease-7 promotes transcription. Proc Natl Acad Sci USA 2013;110(2):618-23
18. Cao P, Weinstock J, Kingsbury WD, et al. Anti-neoplastic compounds, compositions and methods. WO2010114881 A1(PCT/US2010/ 029358): US20120114765; 2010
19. Carmody RJ. Treatment of inflammation. WO2012056048 A1 (PCT/EP2011/069171): EP2446883A1; 2012
20. Colland F, Gourdel M-E. Selective and reversible inhibitors of ubiquitin specific protease 7. WO2013030218 A1(PCT/ EP2012/066741):EP2565186A1, WO2013030218A4; 2013
21. Reverdy C, Conrath S, Lopez R, et al. Discovery of specific inhibitors of human USP7/HAUSP deubiquitinating enzyme. Chem Biol 2012;19(4):467-77
22. Colombo M, Vallese S, Peretto I, et al. Synthesis and biological evaluation of 9-oxo-9H-indeno[1,2-b]pyrazine-2,3- dicarbonitrile analogues as potential inhibitors of deubiquitinating enzymes. ChemMedChem 2010;5(4):552-8
23. Lopez R, Colland F. Amidoacridine derivatives useful as selective inhibitors of ubiquitin specific protease 7. WO2011086178 A1(PCT/EP2011/ 050523): CA2786957A1, CN102781919A, EP2357176A1, EP2523938A1, US20110177105, US30023521; 2011
24. Lopez R, Collura V, Sippl W, Colland F. Novel specific inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications. WO2010081783 A1(PCT/EP2010/ 050223): EP2208725A1; 2010
25. Altun M, Kramer HB, Willems LI, et al. Activity-based chemical proteomics accelerates inhibitor development for deubiquitylating enzymes. Chem Biol 2011;18(11):1401-12
26. Tian X, Sh Isamiddinova N, Peroutka RJ, et al. Characterization of selective ubiquitin and ubiquitin-like protease inhibitors using a fluorescencebased multiplex assay format. Assay Drug Dev Technol 2011;9(2):165-73
27. Yamaguchi M, Miyazaki M, Kodrasov MP, et al. Spongiacidin C, a pyrrole alkaloid from the marine sponge Stylissa massa, functions as a USP7 inhibitor. Bioorg Med Chem Lett 2013;23(13):3884-6
28. Weinstock J, Wu J, Cao P, et al. Selective dual inhibitors of the cancerrelated deubiquitylating proteases USP7 and USP47. ACS Med Chem Lett 2012;3(10):789-92
29. Dar A, Shibata E, Dutta A. Deubiquitination of Tip60 by USP7 determines the activity of the p53-dependent apoptotic pathway. Mol Cell Biol 2013;33(16):3309-20
30. FORMA Therapeutics and CRT to discover cancer drugs targeting deubiquitinating enzymes (DUBs). Cancer Res Technol 2013; Available from: http://www.cancerresearchuk.org/about-us/ cancer-news/press-release/ formatherapeutics- and-cancer-researchtechnology- to-discover-cancer- drugstargeting
31. Delivering highly innovative cancer therapeutics targeting ubiquitin pathways involved in the DNA damage response. Mission Ther 2013; Available from: http://www. missiontherapeutics.com